Current Challenges in Monitoring the Safety and Utilisation of the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A UK Perspective
Drug Safety · 2026-09 · 49 (9) · 1005-1008
DOI: 10.1007/s40264-026-01676-4 ↗Kurz gefasst
Editorial in der Zeitschrift Drug Safety, online erschienen am 05.05.2026. Verfasst von Miranda Davies und 1 weiteren Autor:innen. Beteiligte Einrichtung: Drug Safety Research Unit, Southampton, UK. miranda.davies@dsru.org. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Drug Safety Research Unit, Southampton, UK. miranda.davies@dsru.org.
- School of Medicine, Pharmacy, and Biomedical Science, University of Portsmouth, Portsmouth, UK. miranda.davies@dsru.org.
- Drug Safety Research Unit, Southampton, UK.
- School of Medicine, Pharmacy, and Biomedical Science, University of Portsmouth, Portsmouth, UK.
Zitieren
APA
Davies, M., & Härmark, L. (2026). Current Challenges in Monitoring the Safety and Utilisation of the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A UK Perspective. Drug Safety, 49(9), 1005-1008. https://doi.org/10.1007/s40264-026-01676-4
Vancouver
Davies M, Härmark L. Current Challenges in Monitoring the Safety and Utilisation of the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A UK Perspective. Drug Safety. 2026;49(9):1005-1008. doi:10.1007/s40264-026-01676-4
BibTeX
@article{Davies2026,
author = {Davies, Miranda and Härmark, Linda},
title = {Current Challenges in Monitoring the Safety and Utilisation of the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A UK Perspective},
journal = {Drug Safety},
year = {2026},
volume = {49},
number = {9},
pages = {1005--1008},
doi = {10.1007/s40264-026-01676-4}
}
EUVIMED